All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On Tuesday 4th June an oral abstract session took place at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. During that session, Abstract 7503 was presented by Nobert Shmitz, University Hospital Münster, Münster, DE, on the final analysis of the AATT study (2007-001052-39), which was conducted by the French Lymphoma Study Association (LYSA) and the German Lymphoma Alliance (GLA). This trial compared the efficacy of allogeneic stem cell transplantation (allo-SCT) to autologous stem cell transplantation (Auto-SCT), as first line consolidation in patients with T-cell lymphomas.
Baseline characteristic |
Auto-SCT cohort |
Allo-SCT cohort |
Total cohort |
---|---|---|---|
Median age (range) |
50 (28–60) |
50 (24–60) |
50 ( 24–60) |
Male patients |
57% |
69% |
63% |
ECOG > 1 |
20% |
20% |
20% |
Disease stage III–IV |
87% |
90% |
88% |
Extranodal disease |
59% |
63% |
61% |
Disease diagnosis: PTCL, not-otherwise specified (NOS)
AITL
ALCL, ALK-negative
Other TCL |
28%
33%
17%
24% |
31%
43%
11%
18% |
29%
38%
14%
21% |
Response |
Auto-SCT cohort (n = 54) |
Allo-SCT cohort (n = 49) |
Total (N = 103) |
---|---|---|---|
CR & unconfirmed CR (CRu) |
39% (n = 21) |
51% (n = 25) |
45% (n = 46) |
CR/CRu & PD within 2 months |
2% (n = 1) |
2% (n = 1) |
2% (n = 2) |
PR |
17% (n = 9) |
8% (n = 4) |
13% (n = 13) |
PD |
33% (n = 18) |
31% (n = 15) |
32% (n = 33) |
Unknown |
6% (n = 3) |
0% (n = 0) |
3% (n = 3) |
Treatment-related death |
0% (n = 0) |
8% (n = 4) |
4% (n =4) |
Cause of death |
Auto-SCT cohort |
Allo-SCT cohort |
Total cohort |
---|---|---|---|
Lymphoma |
24% |
22% |
22% |
Treatment-related mortality (TRM; study treatment only) |
0% |
16% |
21% |
TRM (salvage) |
7% |
4% |
14% |
Secondary neoplasia |
2% |
0% |
3% |
Total |
33% |
43% |
45% |
Cause of death |
Auto-SCT cohort |
Allo-SCT cohort |
Total cohort |
---|---|---|---|
Lymphoma (n) |
7 |
1 |
8 |
Secondary neoplasia (n) |
1 |
0 |
1 |
TRM (study treatment only) (n) |
0 |
8 |
8 |
Total (n) |
8 |
9 |
17 |
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox